The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
S. Y. Barbour
Consultant or Advisory Role - Eisai
G. R. Morrow
No relevant relationships to disclose
R. Ahmed
Employment or Leadership Position - Eisai
G. Ballinari
No relevant relationships to disclose
M. D. Thorn
Consultant or Advisory Role - Helsinn Therapeutics
D. Cox
Employment or Leadership Position - Eisai
L. S. Schwartzberg
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai